Detalhe da pesquisa
1.
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Blood
; 139(23): 3366-3375, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081255
2.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
N Engl J Med
; 381(18): 1728-1740, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31665578
3.
Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
Int J Clin Oncol
; 26(11): 2131-2141, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363558
4.
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
J Urol
; 199(1): 147-154, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28827103
5.
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Lancet Oncol
; 17(2): 153-163, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26774508
6.
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
Prostate
; 75(8): 836-44, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25683285
7.
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
J Clin Oncol
; 42(15): 1766-1775, 2024 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38471061
8.
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
J Clin Oncol
; 41(26): 4236-4246, 2023 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37379495
9.
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.
Transplant Cell Ther
; 29(4): 265.e1-265.e10, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36526260
10.
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.
Blood Cancer J
; 12(5): 84, 2022 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35637252
11.
Spectroscopic microvascular blood detection from the endoscopically normal colonic mucosa: biomarker for neoplasia risk.
Gastroenterology
; 135(4): 1069-78, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18722372
12.
Investigating population risk factors of pancreatic cancer by evaluation of optical markers in the duodenal mucosa.
Dis Markers
; 25(6): 313-21, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19208949
13.
Spectral slope from the endoscopically-normal mucosa predicts concurrent colonic neoplasia: a pilot ex-vivo clinical study.
Dis Colon Rectum
; 51(9): 1381-6, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18536963
14.
Optical markers in duodenal mucosa predict the presence of pancreatic cancer.
Clin Cancer Res
; 13(15 Pt 1): 4392-9, 2007 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17671121
15.
Angiotensin receptor blockade and arterial compliance in chronic kidney disease: a pilot study.
Am J Nephrol
; 25(4): 393-9, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16088080